hep C
AbbVie sue NHS over hepatitis C drug procurement
November 8, 2018Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling
American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …
Medicines Patent Pool to include hep C and TB drugs
November 9, 2015Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis
The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …
China rejects Gilead’s Sovaldi patent
June 24, 2015Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi
Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …
$10 generic Solvaldi emerges in Bangladesh
March 10, 2015Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
AbbVie Hep C combo pill ready for Europe
January 16, 2015Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi
The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
BMS claims advance with hepatitis C regimen
November 10, 2014Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi
Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …
Sovaldi misses estimates but still makes history
October 29, 2014Research and Development, Sales and Marketing FDA, Gilead, harvoni, hep C, sofosbuvir, sovaldi
The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …
Merck revenue falls
October 28, 2014Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi
Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …
BMS pulls hep C combo treatment in US
October 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi
Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
Sovaldi ‘unaffordable’ says NHS documents
October 7, 2014Medical Communications, Research and Development, Sales and Marketing NHS England, fund, hep C, sovaldi
Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after …
Latest content
FibroFind appoints Lee Borthwick as CEO
